Costs associated with second-line therapies for lung cancer

American Journal of Pharmacy Benefits

Volumn 3, Issue 1, 2011, Pages 21-33

  Lash, Stephen ^a   Teitelbaum, April ^b   Henk, Henry J ^c   Reyes, Carolina M ^a   Benn, Lucinda ^a  

^a GENENTECH INC   (United States)

^b i3 Global   (Canada)

^c i3 Innovus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; PEMETREXED;

ADULT; AGE DISTRIBUTION; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; COMORBIDITY; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG COST; DRUG ERUPTION; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GEOGRAPHY; HEALTH CARE COST; HUMAN; LEUKOPENIA; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; RETROSPECTIVE STUDY; SEX RATIO; THORAX PAIN; TREATMENT DURATION; TREATMENT INDICATION; VOMITING;

EID: 79951490273     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. International Agency for Research on Cancer. GLOBOCAN 2008. CANCERMondial. October 2009. http://www-dep.iarc.fr. Accessed March 9, 2010.
2. American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: American Cancer Society; 2010.
3. Stat bite: lung cancer stage at diagnosis in the United States, 1995-2001. J Natl Cancer Inst. 2005;97(24):1805.
4. Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9(3):222-231.
5. National Cancer Institute. Cancer trends progress report-2009/2010 update. Costs of cancer care. April 2010. http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2007&chid=75&coid=726&mid=. Accessed January 24, 2011.
6. Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143-154.
7. Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care. 2008;14(9):565-571.
8. Chouaid C, Atsou K, Hejblum G, Vergnenegre A. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics. 2009;27(2):113-125.
9. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524-3530.
10. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Secondline and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care. 2008;14(5):297-306.
11. Hillner BE, McDonald MK, Desch CE, et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol. 1998;16(4):1420-1424.
12. Socinski MA, Crowell R, Hensing TE, et al; American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 suppl):277S-289S.
13. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123(1 suppl):226S-243S.
14. Pfister DG, Johnson DH, Azzoli CG, et al; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-smallcell lung cancer guideline: update. 2003. J Clin Oncol. 2004;22(2):330-353.
15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3. Fort Washington, PA: NCCN; 2011.
16. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group [published correction appears in J Clin Oncol. 2004;22(1):209]. J Clin Oncol. 2000;18(12):2354-2362.
17. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004;43(2):183-194.
18. de Marinis F, Grossi F. Clinical evidence for second-and third-line treatment options in advanced non-small cell lung cancer. Oncologist. 2008;13(suppl 1): 14-20.
19. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10): 2095-2103.
20. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597.
21. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
22. Bezjak A, Tu D, Seymour L, et al; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 [published correction appears in J Clin Oncol. 2007;25(1):167]. J Clin Oncol. 2006;24(24):3831-3837.
23. Smit EF, Mattson K, von PJ, Manegold C, Clarke S, Postmus PE. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol. 2003;14(3):455-460.
24. Tarceva (erlotinib) [package insert]. South San Francisco, CA: Genentech USA Inc; 2010.
25. Taxotere (docetaxel) [package insert]. Bridgewater, NJ: sanofi-aventis US; 2010.
26. Alimta (pemetrexed) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2010.
27. Ng R, Loreto M, Lee R, Leighl NB. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer. 2008;61(2):262-265.
28. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(4):430-440.
29. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory nonsmall cell lung cancer (NSCLC). Lung Cancer. 2008;61(3):405-415.
30. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm. 2006;12(6):472-478.
31. Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 2010;28(1):75-92.
32. 104th Congress. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191.1996. http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Accessed January 12, 2010.
33. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
34. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18(2):153-171.
35. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17(3):283-295.
36. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL: Chapman & Hall/CRC; 1993.